Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
Pain Ther
.
2025 Feb;14(1):441-444.
doi: 10.1007/s40122-024-00692-5.
Authors
Andrew M Blumenfeld
1
2
,
Laszlo Mechtler
3
,
Lisa Cook
4
,
Christopher Rhyne
5
,
Brian Jenkins
6
,
Olivia Hughes
7
,
Brett Dabruzzo
8
,
Aubrey Manack Adams
8
,
Merle Diamond
9
Affiliations
1
The Los Angeles Headache Center, Los Angeles, CA, USA.
[email protected]
.
2
The San Diego Headache Center, San Diego, CA, USA.
[email protected]
.
3
Dent Neurologic Institute, Buffalo, NY, USA.
4
The Los Angeles Headache Center, Los Angeles, CA, USA.
5
Norton Neuroscience Institute, Louisville, KY, USA.
6
Neuroscience Group, Neenah, WI, USA.
7
ICON Plc, Blue Bell, PA, USA.
8
AbbVie, North Chicago, IL, USA.
9
Diamond Headache Clinic, Chicago, IL, USA.
PMID:
39718742
PMCID:
PMC11751245
DOI:
10.1007/s40122-024-00692-5
No abstract available
Publication types
Published Erratum